{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:26:45Z","timestamp":1766503605682,"version":"build-2065373602"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Trifluridine\/tipiracil (FTD\/TPI) plus bevacizumab (BEV) is a standard third-line therapy for unresectable advanced or recurrent colorectal cancer. The standard dosing schedule (5 days of administration followed by 2 days off) is associated with a high incidence of severe neutropenia. Conversely, a biweekly dosing schedule (5 days of administration followed by 9 days off) reportedly reduces this incidence. However, no direct comparison of these regimens has been made. In this study, we retrospectively compared the efficacy and safety of these two dosing schedules.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from patients who received FTD\/TPI + BEV treatment between June 2016 and January 2024 at three hospitals affiliated with Fujita Health University. The effects of the dosing schedules on hematological toxicity, overall survival (OS), and time to treatment failure (TTF) were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 125 patients, 26 and 99 were classified into the standard and biweekly groups, respectively. Grade \u2265 3 neutropenia occurred in 50.0% of patients in the standard group and 29.3% of those in the biweekly group (P = .062), with multivariable analysis confirming the dosing schedule impact (P = .048). Median TTF was 5.4 and 7.0 months, while median OS was 16.4 and 14.5 months (P = .908, 0.947) in the standard and biweekly groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The biweekly regimen of FTD\/TPI + BEV resulted in a lower tendency for severe neutropenia than that in the standard regimen, while maintaining comparable OS and TTF in patients with unresectable advanced or recurrent colorectal cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf108","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T03:58:48Z","timestamp":1751947128000},"page":"1105-1111","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of standard and biweekly trifluridine\/tipiracil plus bevacizumab regimens in advanced or recurrent colorectal cancer: a retrospective study"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-8165","authenticated-orcid":false,"given":"Yosuke","family":"Ando","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaho","family":"Orito","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Kinjo Gakuin University , 2\u20111723 Omori, Moriyama\u2011ku, Nagoya, Aichi 463\u20118521 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Innovative and Clinical Research Promotion Center, Gifu University Hospital ,","place":["1\u20111 Yanagido, Gifu\u2011shi, Gifu 501\u20111194, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanaho","family":"Hiraga","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University Okazaki Medical Center ,","place":["1 Gotanda, Harisaki\u2011cho, Okazaki\u2011shi, Aichi 444\u20110827, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenichi","family":"Morise","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University Okazaki Medical Center ,","place":["1 Gotanda, Harisaki\u2011cho, Okazaki\u2011shi, Aichi 444\u20110827, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Fujita Health University Bantane Hospital , 3\u20116\u201110 Otoubashi, Nakagawa\u2011ku, Nagoya, Aichi 454\u20118509 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]},{"name":"College of Pharmacy, Kinjo Gakuin University , 2\u20111723 Omori, Moriyama\u2011ku, Nagoya, Aichi 463\u20118521 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine , 1\u201198 Dengakugakubo, Kutsukake\u2011cho, Toyoake\u2011shi, Aichi 470\u20111192 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025100708163828400_ref1","volume-title":"Japanese Society for Cancer of the Colon and Rectum. Japanese guidelines for the treatment of colorectal cancer","year":"2024"},{"key":"2025100708163828400_ref2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100708163828400_ref3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100708163828400_ref4","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","article-title":"Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study)","volume":"25","author":"Satake","year":"2020","journal-title":"Oncologist"},{"key":"2025100708163828400_ref5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s10147-022-02243-4","article-title":"Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: A phase II, multicenter, clinical trial (TAS-CC4 study)","volume":"27","author":"Matsuoka","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2025100708163828400_ref6","doi-asserted-by":"publisher","first-page":"17931","DOI":"10.1038\/s41598-023-45244-7","article-title":"Renal impairment as a risk factor for trifluridine\/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study","volume":"13","author":"Shiroyama","year":"2023","journal-title":"Sci Rep"},{"key":"2025100708163828400_ref7","volume-title":"Japanese Society of Medical Oncology (JSMO). Guidelines for the Management of Febrile Neutropenia","year":"2022","edition":"3rd"},{"key":"2025100708163828400_ref8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16917","article-title":"Comparative efficacy and safety of standard and biweekly trifluridine\/tipiracil regimen in patients with colorectal cancer","volume":"44","author":"Hara","year":"2024","journal-title":"Anticancer Res"},{"key":"2025100708163828400_ref9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2217\/fon.15.276","article-title":"TAS-102: A novel antimetabolite for the 21st century","volume":"12","author":"Uboha","year":"2016","journal-title":"Future Oncol"},{"key":"2025100708163828400_ref10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/PPO.0b013e3181d7e8e5","article-title":"Surgical treatment of hepatic colorectal metastasis: Evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century","volume":"16","author":"Ito","year":"2010","journal-title":"Cancer J"},{"key":"2025100708163828400_ref11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for colorectal metastases: Liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr Probl Surg"},{"key":"2025100708163828400_ref12","doi-asserted-by":"crossref","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"2025100708163828400_ref13","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"2025100708163828400_ref14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100708163828400_ref15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5114\/wo.2020.100222","article-title":"Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer","volume":"24","author":"Blazevic","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"key":"2025100708163828400_ref16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10120-011-0032-6","article-title":"Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer","volume":"14","author":"Shim","year":"2011","journal-title":"Gastric Cancer"},{"key":"2025100708163828400_ref17","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025100708163828400_ref18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16291","article-title":"Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: A systematic review and meta-analysis","volume":"8","author":"Bowen","year":"2017","journal-title":"Oncotarget"},{"key":"2025100708163828400_ref19","first-page":"249","article-title":"An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA","volume":"13","author":"Emura","year":"2004","journal-title":"Int J Mol Med"},{"key":"2025100708163828400_ref20","first-page":"6","volume-title":"Summary of nonclinical studies for Lonsurf combination tablets. Module 2 of the common technical document (CTD)","author":"Pharmaceuticals and Medical Devices Agency (PMDA)","year":"2025"},{"key":"2025100708163828400_ref21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/17512433.2016.1133285","article-title":"A novel antimetabolite: TAS-102 for metastatic colorectal cancer","volume":"9","author":"Miyamoto","year":"2016","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1105\/63695747\/hyaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1105\/63695747\/hyaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:16:51Z","timestamp":1759839411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/10\/1105\/8191724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf108","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,8]]}}}